Service Corporation International

---

source: coverage-next-full ticker: SCI company: Service Corporation International step: 01 title: Business Overview & Value Chain date: 2026-05-27

Step 01 — Business Overview: Service Corporation International (SCI)

1. Executive Summary

Service Corporation International (SCI) is the largest death care services company in North America, operating funeral homes, cemeteries, and cremation centers. Founded in 1962 by Robert Waltrip in Houston, Texas, SCI has grown from a single funeral home to a 1,489-location funeral network and 496-cemetery portfolio through disciplined, decades-long consolidation [S1]. The company's competitive position is grounded in three structural advantages: (1) its unmatched geographic scale under the Dignity Memorial brand, (2) a $17.0 billion preneed contract backlog providing exceptional future revenue visibility, and (3) irreplaceable real estate assets in the cemetery business [S2].

2. Business Model

SCI operates a two-segment model:

Segment 1: Funeral (~55.8% of 2025 revenue)

• Provides full-service funeral and cremation arrangements, both at-need (immediate death) and preneed (pre-arranged)
• Revenue sources: funeral services, casket sales, flower sales, transportation, memorialization
• Key brands: Dignity Memorial (full-service), National Cremation Society, Neptune Society (cremation)
• Revenue per call (average): ~$5,500–$6,000 (traditional); ~$2,000–$3,000 (direct cremation)
• 2025 funeral revenue: ~$2,406M; gross margin: ~20.6%

Segment 2: Cemetery (~44.2% of 2025 revenue)

• Sells cemetery property (burial plots, niches, mausoleums) and provides interment services
• Also sells pre-need property rights (cemetery real estate sold well in advance)
• Higher margins than funeral due to real estate component
• 2025 cemetery revenue: ~$1,904M; gross margin: ~33.8%

3. Value Chain Layer Map

[UPSTREAM]
  Merchandise procurement (caskets, urns, vaults, flowers)
  Insurance carrier partnerships (preneed insurance funding)
  Cemetery land acquisition and perpetual care
  Funeral home acquisitions

[OPERATIONS CORE]
  Funeral directors (licensed professionals — state regulated)
  Cremation technicians
  Cemetery managers and groundskeepers
  Preneed sales counselors (commissioned sales force)
  Trust fund management (state-mandated trusts for preneed funds)

[CUSTOMER DELIVERY]
  At-need funeral arrangements (48–72 hour urgency)
  Cremation processing
  Cemetery interments and memorialization
  Grief support services

[DOWNSTREAM / FOLLOW-ON]
  Preneed contract fulfillment (future revenue recognition)
  Trust fund investment returns
  Adjacent plot sales to family members of existing customers
  Preneed insurance claims (insurance-funded preneed)

4. Revenue Model Detail

At-Need Revenue: Recognized at time of service delivery; driven by death volume × average revenue per call. Subject to quarterly volatility from flu seasons, COVID waves, etc.

Preneed Revenue Recognition: Complex multi-step:

1. Customer signs preneed contract and pays
2. Cash deposited into state-mandated trust or used to purchase insurance policy
3. Revenue recognized upon delivery of the service (at death), not at sale
4. Trust fund investment returns flow into revenue as earned
5. Cemetery property (real estate) is recognized at time of sale (distinct from services)

Trust & Insurance Backlog: $17.0B preneed backlog (2025) represents contracts sold but not yet delivered. This is locked-in future revenue that will be recognized at death. ~$8.2B sits in trust assets (2025).

5. Operating Locations (March 2025)

Category	Count	Geography
Funeral service locations	1,489	42 states, 8 Canadian provinces, DC, PR
Cemeteries	496	44 states, 8 Canadian provinces
Combination (funeral + cemetery)	~80+	Co-located

6. Preneed Sales Engine

SCI's preneed sales force is a key differentiator:

• ~3,500 preneed sales counselors (estimate)
• Both funeral preneed and cemetery preneed sold in advance
• 2025 preneed funeral production: $1,198M
• 2025 preneed cemetery production: $1,421M
• Total 2025 preneed production: ~$2,619M

Preneed sales lock in future volume, reduce at-need volume dependency, and create an annuity-like backlog.

7. Key Brand Portfolio

Brand	Positioning
Dignity Memorial	Premium full-service funeral/cemetery (flagship)
National Cremation Society	Affordable cremation specialist
Neptune Society	Cremation with scattering at sea option
Funeraria del Angel	Hispanic communities
Dignity Planning	Online preneed planning platform

8. Strategic Positioning

SCI competes primarily on trust, brand recognition, and geographic convenience rather than price. Key strategic thrusts:

1. Cremation monetization: Growing cremation volume while maintaining revenue per call through ancillary products and preneed
2. Preneed expansion: Higher preneed penetration increases backlog and reduces at-need volatility
3. Bolt-on M&A: ~20–30 funeral homes and occasional cemeteries acquired annually
4. Capital return: ~$600M+ returned to shareholders annually (buybacks + dividends)
5. Technology: Online funeral planning tools, e-commerce for flowers/merchandise

9. Source Index

ID	Source
S1	SEC 10-K FY2025 (filing date 2026-02-12); SCI operations overview
S2	Q4 2025 Earnings Press Release, Feb 11, 2026; revenue by segment
S3	StockAnalysis.com SCI financials page (accessed 2026-05-27)
S4	Industry analysis via Tavily web search (2026-05-27)

---

source: coverage-next-full ticker: SCI company: Service Corporation International step: 04 title: Financial Quality & Adversarial Research Sweep date: 2026-05-27

Step 04 — Financial Quality & Adversarial Research Sweep: SCI

1. Income Statement Quality Assessment

1a. Revenue Recognition Complexity

SCI's revenue recognition is nuanced and creates legitimate complexity — not manipulation, but analysts must understand it [S1]:

1. Preneed revenue deferral: Cash collected from preneed contracts does NOT flow through revenue at sale. Revenue is only recognized upon service delivery. This creates a large deferred revenue liability ($1.78B on-balance-sheet) and $17B in trust-backed future obligations.
2. Trust fund income: Investment returns on preneed trusts are recognized as revenue in the period earned. This creates volatility tied to capital markets (rising in bull markets, declining in bear markets).
3. Preneed merchandise: Cemetery merchandise (vault, marker) is recognized when installed, not when sold. This creates timing differences.

Assessment: Revenue recognition is conservative and well-established. Deferred revenue model protects consumers and creates strong future visibility.

1b. COVID Distortion

FY2021 results ($4.14B revenue, $803M net income, $4.72 EPS) are materially distorted by elevated COVID-related deaths. Analysts using 2021 as a baseline for trend analysis will overstate SCI's organic growth. The correct baseline is 2022–2025 normalized results:

• Revenue: $4.1–$4.3B (2022–2025 range)
• Gross margin: 26–28% (vs. COVID-inflated 31.9% in 2021)
• Net income: $519–$565M (excluding COVID windfall)

Adjustment: Exclude 2021 when calculating 3-year averages for margin analysis.

1c. EPS vs. Net Income Divergence

EPS grew from $3.53 (2022–2023) to $3.80 (2025) while net income was roughly flat (~$540M). The growth is entirely buyback-driven — shares outstanding declined from 153.9M (2022) to 139.7M (2025), a 9.2% reduction. EPS growth investors should note this is financial engineering, not earnings growth — though disciplined buybacks at these multiples do create value.

2. Balance Sheet Quality Assessment

2a. Debt and Leverage

Metric	2023	2024	2025
Total Long-Term Debt	$4,712M	$4,835M	$5,140M
Cash	$222M	$219M	$244M
Net Debt	~$4,490M	~$4,616M	~$4,896M
EBITDA	$1,262M	$1,263M	$1,327M
Net Debt / EBITDA	3.56x	3.66x	3.69x

Assessment: Leverage is elevated but manageable given the predictability of SCI's OCF ($900M+ annually). The company has consistently maintained ~3.5–4.0x leverage through the cycle. Investment-grade credit rating (Moody's, S&P) allows low-cost debt financing.

Risk: Leverage is rising (~$400M net debt increase in 2025 vs. 2024). At some point, this limits buyback capacity or requires asset sales.

2b. Goodwill Quality

Goodwill increased to $2,169M (2025) from $1,915M (2021), reflecting acquisitions. As a % of total equity: ~132% (goodwill exceeds book equity). This is elevated but common for serial acquirers in service businesses where intangibles (brand, licenses, preneed customer relationships) dominate asset value.

Key question: Has SCI overpaid for acquisitions? See Step 07 for M&A deep dive.

2c. Trust Fund Assets — Largest Balance Sheet Item

SCI's $18.7B total assets (2025) include ~$8.2B in preneed trust investments [S2]. These are offset by corresponding preneed trust liabilities — they are not "free" assets. Net position of trust assets vs. trust liabilities matters for cash generation analysis.

Trust investments: fixed income + equities managed by third parties. Market value fluctuations affect recognized trust income but not balance sheet principal for GAAP.

3. Cash Flow Quality Assessment

3a. Operating Cash Flow vs. Net Income (Reconciliation)

Year	Net Income	OCF	OCF/NI Ratio	Quality
2022	$565M	$826M	1.46x	Good
2023	$537M	$869M	1.62x	Good
2024	$519M	$945M	1.82x	Very Good
2025	$543M	$943M	1.74x	Very Good

OCF consistently exceeds net income by a significant margin, driven by non-cash items (depreciation ~$350M, trust income timing). This is a quality indicator — earnings are being backed by real cash.

3b. Free Cash Flow Analysis

Year	OCF	CapEx	FCF	FCF Margin
2023	$869M	$362M	$507M	12.4%
2024	$945M	$374M	$571M	13.6%
2025	$943M	$389M	$554M	12.9%

Note: CapEx from StockAnalysis (PaymentsToAcquireProductiveAssets); 2025 CapEx of $388.6M confirmed in press release

FCF yield at current $10.6B market cap: ~5.2% (2025 FCF). This is modestly attractive for a high-quality defensive business.

CapEx intensity: ~9% of revenue in maintenance + growth CapEx. Company guides to ~$325M maintenance CapEx for 2026. The ~$65M above maintenance in 2025 represents growth/cemetery development.

4. Adversarial Research Sweep

Examining short theses, lawsuits, investigations, and bear case arguments

4a. California AG Settlement (2024)

Finding: California Attorney General reached a $23M settlement with SCI affiliates for violations of Unfair Competition Law and False Advertising Law related to preneed cremation marketing. Alleged misleading sales practices around direct cremation packages [S3].

Assessment: $23M is ~2.5% of a single year's OCF — immaterial financially. However, it raises questions about SCI's aggressive preneed sales practices. Company agreed to comprehensive injunctive relief and full customer restitution. Risk to watch: Similar state investigations in FL, TX, NY where SCI has large concentration.

4b. Preneed Marketing Controversy — Recurring Pattern

Industry critics and state regulators periodically investigate death care companies for high-pressure preneed sales tactics targeting elderly consumers. SCI has faced:

• State-level investigations in multiple jurisdictions historically
• Consumer complaint databases show recurring issues with preneed sales counselor conduct
• FTC Funeral Rule complaints

Assessment: Systemic risk, not idiosyncratic to one event. Manageable if company maintains compliance culture.

4c. Bear Case: Cremation Revenue Compression

The most serious structural bear argument: cremation mix will rise to 80%+ by 2045, compressing revenue per call by 40–50% over two decades. Even with pricing discipline, lower-cost cremation fundamentally changes unit economics.

Counter: (1) SCI is pricing cremation profitably; (2) cemetery remains burial/memorialization focused even for cremated remains; (3) preneed pricing locks in today's rates; (4) volume tailwind partially offsets per-call compression.

Assessment: Real, long-term headwind. Not existential, but limits revenue growth potential. Market appears to have appropriately discounted this.

4d. Debt Accumulation Concern

Net debt grew from ~$3.7B (2020) to ~$4.9B (2025) — a $1.2B increase over 5 years while the company has generated ~$4.5B in cumulative OCF. The debt growth is explained by $2.9B in buybacks, $900M in dividends, and $560M in acquisitions — net $4.4B returned/deployed vs. $4.5B OCF. Leverage is rising but is a deliberate financial policy, not operational deterioration.

Assessment: At 3.9x Net Debt/EBITDA, SCI is at the high end of management's target. A recession or investment-grade credit downgrade could increase interest costs. Watch if Net Debt/EBITDA approaches 4.5x.

4e. SCI Not a Growth Story

Short sellers and value skeptics point out: SCI's revenue has grown just 4.0% total from 2022 to 2025 ($4.11B → $4.31B), essentially flat. Post-COVID normalization means the company faces a multi-year period of slow revenue growth. EPS "growth" is entirely financial engineering (buybacks).

Assessment: Accurate. SCI is a capital allocator and income stock, not a growth stock. The bullish case depends on: (1) demographic tailwind materializing 2028+; (2) pricing power continuing; (3) buybacks at current low P/E accreting to value. Investors expecting revenue growth will be disappointed.

5. Accounting Policy Notes

Policy	SCI Treatment	Industry Norm
Preneed revenue recognition	Conservative deferred model	Same across industry
Trust fund accounting	Per-state trust regulations	Same
Goodwill amortization	None (GAAP, tests for impairment)	Same
Depreciation	Straight-line on PP&E	Same
SBC	Equity-based; $18M/yr (minimal)	Same

No material accounting concerns identified. SCI's financials are clean and consistent.

6. Financial Quality Score

Dimension	Score (1–5)	Notes
Revenue quality	4	Deferred model is conservative; trust income adds some noise
Earnings quality	4	OCF > NI consistently; minimal accruals manipulation
Balance sheet quality	3	Elevated leverage; goodwill large relative to equity
Cash flow quality	5	FCF consistently $500–$575M; well-covered dividend
Accounting transparency	4	Complex preneed reporting but well-disclosed
Overall	4/5	High-quality business; leverage is main risk

7. Source Index

ID	Source
S1	StockAnalysis.com income statement + SCI 10-K revenue recognition notes
S2	XBRL data: trust investments ($8.2B), total assets ($18.7B) — 2025
S3	California AG settlement — Tavily web search (2026-05-27)
S4	Q4 2025 Press Release — OCF $943M, capex $388.6M, buybacks $461M
S5	XBRL: Net income, OCF (2022–2025); StockAnalysis FCF series

---

source: coverage-next-full ticker: SCI company: Service Corporation International step: 12 title: Catalysts & Bull/Bear Analysis date: 2026-05-27

Step 12 — Catalysts & Bull/Bear Analysis: SCI

Note: Earnings transcript analysis was not performed on this research path (coverage-next-full). Bull/Bear debate is inferred from consensus notes, press releases, filings, and recent analyst coverage.

1. Current Market Debate

The market consensus on SCI is "Strong Buy" with ~25% implied upside (avg target $96.33 vs. $76.87 price). The debate centers on three dimensions:

1. Volume recovery timeline: Q1 2026's -6.6% funeral volume decline raised questions about whether COVID pull-forward normalization will persist through 2026 or whether the underlying business is deteriorating
2. Cremation mix compression: How quickly does revenue/call decline as cremation mix rises beyond 65%?
3. Leverage and buyback sustainability: At $5.2B net debt, can SCI continue $400–500M buybacks per year? What happens if interest rates spike?

2. Near-Term Catalysts (12 Months)

Catalyst	Type	Probability	Impact
Funeral volume recovery in Q2–Q4 2026	Positive	Medium (60%)	EPS toward upper range of $4.05–$4.35 guidance
Cemetery preneed acceleration continues (Q1 +10%)	Positive	Medium-High (70%)	Backlog grows; future revenue visibility improves
Accretive acquisition announcement	Positive	High (80%)	~$50–200M bolt-on; buyback pacing note
EPS guidance raise in Q2/Q3 2026	Positive	Low-Medium (35%)	Stock re-rating possible
California-type regulatory action in another state	Negative	Low-Medium (25%)	One-time charge $15–50M; sentiment hit
Leverage increase above 4.0x Net Debt/EBITDA	Negative	Low (20%)	Rating concern; buyback reduction

3. Medium-Term Catalysts (2–4 Years)

Catalyst	Type	Potential Impact
Baby boomer mortality acceleration (2028–2030)	Positive	+2–4% volume/year; could add $150–300M incremental revenue
Cremation memorialization products take-up	Positive	Offsets per-call revenue compression
Preneed backlog reaching $20B+	Positive	Multi-year revenue visibility; valuation re-rate
Successful Dignity Planning digital platform	Positive	Lower CAC for preneed; higher preneed conversion
Acquisition of large regional cemetery chain	Positive	Transformative; adds cemetery land value

4. Analyst Debate — Key Fault Lines

Reconstructed from consensus data and filings (no transcripts available)

Bull Side Arguments:

• SCI is the "ultimate demographic play" — baby boomers dying is an investment thesis with near-certainty
• $17B preneed backlog provides unmatched revenue visibility (>4x annual revenue)
• Management has delivered 8–12% EPS growth long-term through pricing + buybacks
• Current stock at $77 is below 2022 buyback prices; management signaling value with repurchase activity
• Cemetery land is a real asset with inflationary value; long-term holders benefit from embedded appreciation

Bear Side Arguments:

• Revenue growth is essentially zero in real terms; EPS growth is buyback-dependent
• Leverage is rising (3.73x Net Debt/EBITDA, above management's comfort midpoint)
• Cremation commoditization is a structural headwind that will accelerate over the next decade
• At 20x trailing P/E, SCI is not cheap enough to own given the cremation risk and leverage
• California AG action signals broader regulatory risk; preneed marketing practices are aggressive

5. Variant Perception

The market appears to have correctly priced in the cremation mix headwind and post-COVID volume normalization. The underappreciated variant is:

1. Boomer wave timing: Street models assume ~1% volume growth per year through 2027. The actual boomer mortality acceleration may arrive earlier (2027–2028 onset), providing upside surprise.

2. Cemetery business quality: The market undervalues SCI's cemetery segment. Cemetery land is non-replicable, margin-accretive, and benefits from both traditional burial AND cremation memorialization. As cremation rises, the cemetery business diversifies into cremation gardens, scatter gardens, and memorial walls — protecting its economic contribution.

3. Preneed trust returns: With higher interest rates, SCI's $8.2B trust portfolio generates higher returns, boosting recognized revenue. This benefit is partly overlooked in modeling.

6. Short Interest & Contrarian View

• Short interest: Low (death care companies are not typical hedge fund short targets)
• No known activist investor campaigns
• No meaningful options market signal suggesting imminent catalyst

The lack of short interest confirms the market views this as a stable, low-volatility compounder — not a contested company.

---

Bull Case — 3 Bullets

• Demographic tailwind materializes early: Baby boomer mortality accelerates to 2027–2028 (earlier than consensus); funeral volume inflects positive at +2–3% per year while SCI's pricing power continues at +3%; combined revenue growth reaches 5–6% annually, driving EBITDA to $1.5B+ by 2028 and EPS to $5.50–$6.00. Stock re-rates to 22x forward P/E = $110–$130 range.

• Preneed machine continues compounding: Cemetery preneed sales production sustains +8–10% growth (Q1 2026 trend) as digital platform (Dignity Planning) reduces acquisition costs; backlog grows to $20B by 2027; management raises long-term EPS growth target to 10–14%; buybacks continue at $400–500M/yr reducing share count to ~130M by 2027.

• Capital allocation excellence is re-rated: Market recognizes SCI's free cash flow yield (~5.2%), disciplined M&A, and growing dividend as a "Berkshire of death care" compounder; P/FCF re-rates from 19x to 22x; combined with ~$4.50 FCF/share by 2027, stock reaches $99–$110.

---

Bear Case — 3 Bullets

• Cremation commoditization accelerates faster than expected: Direct cremation providers (Tulip, Final Goodbye) capture 25%+ of the market below SCI's price floor; SCI's funeral revenue/call declines 5–7% annually as cremation mix hits 70% by 2028; operating income stagnates near $950M; EPS growth limited to 3–4%; stock de-rates to 17x earnings = $68–$72.

• Leverage trap if rates remain elevated or rise: SCI refinances $1–2B of near-term maturities at 5.5–6.5% (vs. current ~5.0% portfolio rate); interest expense rises to $300–$330M; FCF compresses to $450–$500M; buyback pace cut to $200–$250M; EPS growth slows to 3–5%; multiple compresses; stock revisits $65–$70.

• Regulatory and compliance headwinds mount: Following California AG precedent, Florida, Texas, and New York AGs investigate preneed sales practices; total settlements/fines reach $75–$150M over 2026–2028; reputational damage reduces preneed sales conversion; management distraction from legal defense; stock de-rates 15–20% from announcement effect; floor ~$62–$68.

---

7. Source Index

ID	Source
S1	StockAnalysis.com forecast — consensus EPS, price targets, analyst rating
S2	Q1 2026 earnings highlights — gurufocus.com (May 2026)
S3	Q4 2025 Press Release — cemetery preneed +10% Q1 signal
S4	Moat analysis (Step 10) and External Risk Overlay (Step 11)
S5	Industry analysis — Tavily search (cremation rates, competitive dynamics)